Topical Itraconazole in the Treatment of Basal Cell Carcinoma

Inclusion Criteria: * Participants must be over the age of 18 years * Male * Women who do not have child-bearing potential (history of hysterectomy, post-menopausal) * Have a biopsy confirmed BCC that measures at least 6mm in size at the time of the initial evaluation (visit #1); * Participant must be willing and comply with the requirements of the protocol; * Participant must have the ability to understand and communicate with the investigator; * Participant must provide informed consent. Exclusion Criteria: * Subject with significant congestive heart failure (CHF) or history of CHF, chronic renal failure, hepatic failure, neuropathy * Subject with current skin diseases that the investigator feels is not safe for study participation including but not limited to severe atopic dermatitis, cutaneous T-cell lymphoma, erythroderma; * Subjects on systemic medications known to affect the Hedgehog pathway (see Appendix I) * Subjects on cisapride, oral midazolam, nisoldipine, felodipine, pimozide, quinidine, dofetilide, triazolam, methadone, levacetylmethadol (levomethadyl), lovastatin, simvastatin, dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine), cisapride, pimozide, methadone, levacetylmethadol (levomethadyl), quinidine * Subjects with history of hypersensitivity to azoles * Subjects with Gorlin syndrome * Subjects on chronic immunosuppression, or who have a history of compromised immune function (e.g. history of or current malignancy other than BCC/squamous cell skin cancers) * Subjects who do not speak English or have difficulty hearing or are otherwise impaired for providing informed consent and communicating with the investigator; * Subjects with a history of keloids or excessive scarring; * Subjects with known allergy to lidocaine, epinephrine, itraconazole or petrolatum * Women of child-bearing age/potential and/or able to conceive